Lv6
1850 积分 2025-08-24 加入
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI
23天前
已完结
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
23天前
已完结
Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study
23天前
已完结
Survival Outcome of Tyrosine Kinase Inhibitors Beyond Progression in Association to Radiotherapy in Oligoprogressive EGFR-Mutant Non-Small-Cell Lung Cancer
23天前
已完结
Survival Outcome of Tyrosine Kinase Inhibitors Beyond Progression in Association to Radiotherapy in Oligoprogressive EGFR-Mutant Non-Small-Cell Lung Cancer
23天前
已关闭
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer Treated With Osimertinib
23天前
已完结
Survival Outcome of Tyrosine Kinase Inhibitors Beyond Progression in Association to Radiotherapy in Oligoprogressive EGFR-Mutant Non-Small-Cell Lung Cancer
23天前
已关闭
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib
24天前
已完结
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy
24天前
已完结
Radiotherapy of Non-Small-Cell Lung Cancer in the Era of EGFR Gene Mutations and EGF Receptor Tyrosine Kinase Inhibitors
1个月前
已完结
皖公网安备34019202002308
